Diabetic Foot
Recent clinical, regulatory, research and industry developments relating to this disease.
11. Microvascular Complications and Foot Care: <i>Standards of Medical Care in Diabetes-2020</i>.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 6 clinical trials expected to report results, the earliest in Q1 2027.
- Q1 2027A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular Edema
- Q3 2027A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 Diabetes
- Q3 2027Diabetes Diagnosis, Management, Prevention and Education in Guinea-Bissau
- Q3 2027Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR Study
- Q4 2027Beta Cell Function in Type 2 Diabetes in Black Patients: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor Agonists
Clinical MilestonesView all 13Hide
- 2026-06-26A Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-20A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18A 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
- 2026-02-17Diabetes Diagnosis, Management, Prevention and Education in Guinea-BissauResults expected Q3 2027
- 2026-01-13Semaglutide for Dialysis-Treated Patients - a Glucose Time in Range Study- DIALYSIS-TIR StudyResults expected Q3 2027
- 2029-02-28Evaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31Intervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01A Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01Phase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01Comparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2029-02-28ClinicalEvaluate the Efficacy and Safety of the Combined Use of a Sodium-glucose Cotransporter 2 (iSGLT2) Inhibitor and a Dipeptidyl Peptidase-4 (iDPP -4) Inhibitor in the Treatment of Type 2 Diabetes Mellitus in Patients Treated With MetforminWithdrawn
- 2028-07-31ClinicalIntervention for High-normal Blood Pressure in Adults With Type 2 Diabetes-----renal SubstudyWithdrawn
- 2028-03-01ClinicalA Phase 3, Prospective, Adaptive, Randomized, Double-blind, Triple-masked, Parallel, Multicenter Clinical Trial to Evaluate the Efficacy and Safety of the N0750 Compared to Monotherapies in the Treatment of Painful Diabetic Peripheral NeuropathyWithdrawn
- 2028-02-01ClinicalPhase III, Adaptive, Multicenter, Randomized, Superiority, Double-Dummy, Double-Blind Clinical Trial to Evaluate the Efficacy and Safety of a Fixed-Dose Combination of a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor and a Thiazolidinedione in the Treatment of Type 2 Diabetes Mellitus, Compared to Monotherapy, in Patients Treated With MetforminWithdrawn
- 2027-01-01ClinicalComparison of Subvisible Retinal Laser Therapy With Intravitreal Bevacizumab in Treatment of Diabetic Macular EdemaWithdrawn
- 2026-06-30ClinicalMetformin Versus Standard of Care Treatment in Pregnant Women With Prediabetes: A Randomized TrialWithdrawn
- 2026-06-26ClinicalA Randomized, Double-Masked, Multi-Center, 3-Arm Pivotal Phase 2/3 Study to Evaluate The Efficacy and Safety of Intravitreal EYE103 Compared With Intravitreal Ranibizumab (0.5mg) in Participants With Diabetic Macular EdemaResults expected Q1 2027
- 2026-04-20ClinicalA Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared With Placebo in Participants With Obesity or Overweight With and Without Type 2 DiabetesResults expected Q3 2027
- 2026-03-18ClinicalA 96-week, Single-arm Study to Evaluate the Efficacy and Safety of 8mg Aflibercept in Subjects With Proliferative Diabetic Retinopathy (PDR) Without Center-involved Diabetic Macular Edema (DME)Results expected Q1 2028
- 2026-02-17ClinicalDiabetes Diagnosis, Management, Prevention and Education in Guinea-BissauResults expected Q3 2027
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Treatment Ertapenem SUN is indicated in paediatric patients (3 months to 17 years of age)… (2022)
Approval — Tygecycline Accord is indicated in adults and in children from the age of eight years for… (2020)
Approval — This medicinal product is for diagnostic use only and the approved indication is scintigr… (2010)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes5
- Diabetic Foot2
- Cardiovascular Diseases1
- Diabetes Mellitus1
- Diabetes Mellitus, Type 21
- Platelet-Rich Plasma1
Leading journals5
- Circulation1
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
- Diabetes care1
- Diabetes/metabolism research and reviews1
- International wound journal1
Leading researchers8
- Armstrong DG2
- Embil JM2
- Lipsky BA2
- Abbas ZG1
- Aragón-Sánchez J1
- Berendt AR1
- Conte MS1
- Cornia PB1
Affiliations (unnormalised)6
- University of Washington2
- Abbas Medical Centre1
- Alberta Public Laboratories1
- Green Templeton College1
- Gustave Dron Hospital1
- Infection and Immunity Institute1
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Diabetic foot refers to common foot problems in people with diabetes mellitus. It arises from a combination of diabetic neuropathy, peripheral vascular disease, and infection, and can progress from injury or infection to severe ulceration, gangrene, and surgical amputation.
The grounding supports a multifactorial aetiology rather than a single cause. Diabetic foot problems are caused by combinations of diabetic neuropathies, peripheral vascular diseases, and infection, with many diabetic foot infections beginning in a wound, often a neuropathic ulceration.
Loss of sensation and poor circulation are central to the disease process. These changes allow injuries to go unnoticed and impair healing, so wounds can become colonized and then infected, with progression to deeper ulceration, gangrene, and possible amputation.
Diabetes mellitus is the underlying condition associated with risk. The supplied material also supports neuropathic ulceration, poor circulation/peripheral vascular disease, and existing wounds as factors that predispose to infection and severe foot complications.
Management is described at the level of wound and infection care, vascular assessment, and prevention-oriented foot care. For diabetic foot infections, care is guided by infection severity classification and vascular assessment, with escalation to hospitalization, imaging, surgical intervention, or amputation when needed; multidisciplinary diabetic wound and amputation prevention clinics are also emphasized.
AI-generated summary grounded in MeSH and 3 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
Common foot problems in persons with DIABETES MELLITUS, caused by any combination of factors such as DIABETIC NEUROPATHIES; PERIPHERAL VASCULAR DISEASES; and INFECTION. With the loss of sensation and poor circulation, injuries and infections often lead to severe foot ulceration, GANGRENE and AMPUTATION, SURGICAL.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.